These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26633755)

  • 1. Imaging Brain Networks After Cancer and Chemotherapy: Advances Toward Etiology and Unanswered Questions.
    Nudelman KN; McDonald BC; Saykin AJ
    JAMA Oncol; 2016 Feb; 2(2):174-6. PubMed ID: 26633755
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors.
    Kesler SR; Blayney DW
    JAMA Oncol; 2016 Feb; 2(2):185-92. PubMed ID: 26633037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive deficits are usually mild in patients with breast cancer after chemotherapy.
    Barton MK
    CA Cancer J Clin; 2013 Jan; 63(1):3-4. PubMed ID: 23169539
    [No Abstract]   [Full Text] [Related]  

  • 4. Accumulating evidence for the effect of chemotherapy on cognition.
    Rodin G; Ahles TA
    J Clin Oncol; 2012 Oct; 30(29):3568-9. PubMed ID: 22927529
    [No Abstract]   [Full Text] [Related]  

  • 5. Cognitive problems after chemotherapy for breast cancer.
    Harv Womens Health Watch; 2002 Oct; 10(2):5-6. PubMed ID: 12393318
    [No Abstract]   [Full Text] [Related]  

  • 6. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study.
    Hermelink K; Untch M; Lux MP; Kreienberg R; Beck T; Bauerfeind I; Münzel K
    Cancer; 2007 May; 109(9):1905-13. PubMed ID: 17351951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect?
    Ganz PA
    J Natl Cancer Inst; 1998 Feb; 90(3):182-3. PubMed ID: 9462670
    [No Abstract]   [Full Text] [Related]  

  • 8. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Results of a prospective, randomized, longitudinal trial.
    Maruff P; Falleti MG; Collie A
    Cancer; 2004 Nov; 101(9):2143-4; author reply 2144-5. PubMed ID: 15382092
    [No Abstract]   [Full Text] [Related]  

  • 9. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study.
    Biglia N; Bounous VE; Malabaila A; Palmisano D; Torta DM; D'Alonzo M; Sismondi P; Torta R
    Eur J Cancer Care (Engl); 2012 Jul; 21(4):485-92. PubMed ID: 22211832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
    Pritchard KI
    Oncologist; 2009 Oct; 14(10):959-62. PubMed ID: 19819915
    [No Abstract]   [Full Text] [Related]  

  • 11. Does cognitive impairment after chemotherapy for breast cancer improve over time or does practice make perfect?
    Schagen SB; van Dam FS
    J Clin Oncol; 2006 Nov; 24(32):5170-1; author reply 5171-2. PubMed ID: 17093282
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
    Brower V
    J Natl Cancer Inst; 2013 Jun; 105(12):835-6. PubMed ID: 23733910
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclophosphamide and/or Anthracyclines Induced Epiphora in Breast Cancer Patients: A Rare Side-effect.
    Kalra R; Chavada B; Madhani NR; Purohit B; Tripathi CB
    Curr Drug Saf; 2018; 13(1):62-64. PubMed ID: 28933276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced cognitive impairment in women with breast cancer: a critique of the literature.
    Jansen CE; Miaskowski C; Dodd M; Dowling G
    Oncol Nurs Forum; 2005 Mar; 32(2):329-42. PubMed ID: 15759070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Never use anthracyclines with trastuzumab: it is time to reconsider the taboo.
    Gianni L
    Breast Cancer Res Treat; 2009 Oct; 117(3):599-601. PubMed ID: 19387827
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer.
    Hermelink K
    Cancer; 2011 Mar; 117(5):1103; author reply 1103-4. PubMed ID: 20960507
    [No Abstract]   [Full Text] [Related]  

  • 17. Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study.
    Hermelink K; Küchenhoff H; Untch M; Bauerfeind I; Lux MP; Bühner M; Manitz J; Fensterer V; Münzel K
    Psychooncology; 2010 Dec; 19(12):1321-8. PubMed ID: 20127909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective impairment of attention networks in breast cancer patients receiving chemotherapy treatment.
    Chen X; Li J; Ren J; Hu X; Zhu C; Tian Y; Hu P; Ma H; Yu F; Wang K
    Psychooncology; 2014 Oct; 23(10):1165-71. PubMed ID: 24737580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gastrointestinal injuries in patients with breast cancer treated with chemotherapy].
    Koroleva IA; Vel'sher LZ; Kaziulin AN; Kucheriavyĭ IuA; Oganesian TS
    Vopr Onkol; 2010; 56(2):206-9. PubMed ID: 20552899
    [No Abstract]   [Full Text] [Related]  

  • 20. [Management of anthracycline and taxane therapy-induced symptoms for the patients with breast cancer].
    Fukada I; Ito Y
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():548-52. PubMed ID: 25831820
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.